Skip to main content

Advertisement

Figure 3 | BMC Immunology

Figure 3

From: Synthesized OVA323-339MAP octamers mitigate OVA-induced airway inflammation by regulating Foxp3 T regulatory cells

Figure 3

The levels of cytokines in BALF and in the lung. OVA323-339MAP treatment could reverse OVA-induced response, reducing the IL-4, IL-5, and IL-13 levels, increasing the level of IFN-γ and IL-10 and regulating the ratio of IFN-γ/IL-4. For the level of TGF-β1 in BALF, there were no markedly differences in each group, but the TGF-β1 mRNA expression was enhanced significantly after OVA323-339MAP intervention. In addition, the expression levels of IL-10 and Foxp3 in the lung tissue were higher in MAPs group than that of control and OVA groups. (* compared with the control group, P < 0.05; # with the OVA group, P < 0.05). Data represent one of three independent experiments.

Back to article page